# US 2003/0211464 A1 · Method and compositions for drug discovery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211464 A1
- Document ID: US20030211464A1
- Status: Published application
- Kind: A1
- Application number: 10/275,142
- Filed: 2002-11-01
- Published: 2003-11-13
- Earliest claimed: 2002-11-01
- Inventors: Charles Pidgeon
- Web page: https://patentgrep.com/patent/US20030211464A1

## CPC

- G01N 33/54366: {Apparatus specially adapted for solid-phase testing}
- G01N 33/577: involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)}
- G01N 30/7233: {interfaced to liquid or supercritical fluid chromatograph (interfaces in general for introducing or extracting samples to be analysed with specially adapted mass spectrometer, see H01J49/04)}
- G01N 30/8658: {Optimising operation parameters}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A drug-binding substrate formed or identified using a drug substance having a predetermined biological activity is used to screen and identify test compounds likely to exhibit the predetermined biological activity. The potential biologically active test compounds are identified by their specific binding to the drug-binding substrates as detected by any of a wide variety of techniques using labeled or unlabeled assay components. In one embodiment a monoclonal antibody raised against a drug substance is used as a drug-binding substrate to identify and isolate test compounds in a natural product extract or a combinatorial chemical library. Preferably the monoclonal antibody is characterized by its ability to bind specifically to at least one other drug substance having the same or similar biological activity as the drug substance against which it was raised. The invention finds use inter alia in drug discovery protocols, in toxicity profiling of drug substances and in assaying commercial natural products.

## Claims

### Claim 1

A method of identifying new drug substances or lead compounds for new drug substances having a predetermined biological activity in a living species, said method comprising the steps of contacting a test solution comprising an exogenous test compound of unknown biological activity with a drug-binding substrate formed or identified using a drug substance known to exhibit the predetermined biological activity in said species and capable of specific binding to said drug substance, detecting the existence of specific binding of the test compound with the drug-binding substrate, and determining whether the specific binding test compound exhibits the predetermined biological activity.

### Claim 2 (depends on 1)

The method of claim 1 wherein the drug-binding substrate is an antibody or a phage display library.

### Claim 3 (depends on 1)

The method of claim 1 wherein the drug-binding substrate is a monoclonal antibody raised against the drug substance.

### Claim 4 (depends on 3)

The method of claim 3 wherein the antibody specifically binds to a second drug substance having the predetermined biological activity.

### Claim 5 (depends on 1)

The method of claim 1 wherein the test solution comprises an extract of a natural product.

### Claim 6 (depends on 1)

The method of claim 1 wherein the test solution comprises a member of a combinatorial chemical library.

### Claim 7 (depends on 5, 6)

The method of claim 5 or claim 6 wherein the drug-binding substrate is a monoclonal antibody raised against the drug substance.

### Claim 8

A method for screening a test compound or a set of test compounds for potential biological activity, said method comprising the steps of
selecting two drug-binding substrates formed or identified using a drug substance exhibiting said biological activity deriving from specific binding to one or more related endogenous molecules and exhibiting specific binding affinity for said drug substance;
contacting said substrate with a test solution comprising 1) a test compound of unknown biological activity and 2) a known amount of said drug substance, or a second drug substance known to bind to said substrate competitively with said drug substance, for a period of time sufficient to allow specific binding of the drug substance and the drug-binding substrate;
determining whether the test compound blocks binding of the substrate with said first or second drug substance; and
determining whether the test compound that does block said binding exhibits the biological activity.

### Claim 9 (depends on 8)

The method of claim 8 wherein the drug-binding substrate comprises an antibody.

### Claim 10 (depends on 8)

The method of claim 8 wherein the determination of the extent of blocked binding of the drug substance and the substrate comprises the step of measuring the amount of drug substance in the test solution or the amount of drug substance bound to the substrate.

### Claim 11 (depends on 8)

The method of claim 8 wherein the drug-binding substrate exhibits specific binding affinity for at least first and second drug substances having the biological activity.

### Claim 12 (depends on 10)

The method of claim 10 wherein the drug-binding substrate exhibits specific binding affinity for at least first and second drug substances having the biological activity.

### Claim 13 (depends on 8)

The method of claim 8 wherein measurement of the amount of drug substance is carried out by a method comprising chromatographic separation of the test solution after the period of time for specific binding.

### Claim 14 (depends on 8)

The method of claim 8 wherein measurement of the amount of drug substance is carried out by a method comprising mass spectrographic analysis of a fraction of said test solution after the period of time for specific binding.

### Claim 15 (depends on 8)

The method of claim 8 wherein the set of test compounds is a natural product comprising an extract of tissue of plant, fungal, microbial or marine origin, or members of a combinatorial chemical library.

### Claim 16 (depends on 8)

The method of claim 8 wherein a plurality of test solutions comprising test compounds of unknown biological activity are contacted with a plurality of respective unique drug-binding substrates.

### Claim 17

A method for detecting potential toxicity of a new drug substance having a first biological activity, said method comprising the steps of
contacting a test solution comprising said new drug substance with a drug-binding substrate formed or identified using a known drug substance known to exhibit a unique second biological activity, said drug-binding substrate capable of specific binding to said known drug substance;
detecting the existence of specific-binding of the new drug substance to the drug-binding substrate; and
determining whether specific-binding new drug substance exhibits the unique second biological activity.

### Claim 18 (depends on 17)

The method of claim 17 wherein the drug-binding substrate is an antibody capable of specific binding to the known drug substance.

### Claim 19 (depends on 18)

The method of claim 18 wherein the test solution is contacted with a multiplicity of unique substrates each capable of specific binding to known drug substances.

### Claim 20

A method for identifying a drug-binding substrate for use in drug discovery testing, said method comprising the steps of
contacting potential drug-binding substrates with a solution of a drug substance having a known biological activity deriving from its specific binding to one or more related endogenous molecules;
identifying those substrates to which the drug substance exhibits specific binding affinity;
contacting a solution of a second drug substance exhibiting said known biological activity with at least the substrates exhibiting specific binding affinity to said first drug substance; and
identifying those substrates that exhibit specific binding to each of said first and said second drug substances.

### Claim 21

A method for identifying a drug-binding substrate for use in drug discovery testing, said method comprising the step of contacting potential drug-binding substrates with a solution comprising a plurality of drug substances, each having a common biological activity deriving from specific binding to one or more related endogenous molecules, and identifying those substrates which specifically bind to more than one of said drug substances.

### Claim 22 (depends on 20, 21)

The method of claim 20 or claim 21 wherein the potential drug-binding substrates are antibodies.

### Claim 23 (depends on 20, 21)

The method of claim 20 or claim 21 wherein the potential drug-binding substrates are monoclonal antibodies.

### Claim 24 (depends on 20, 21)

The method of claim 20 or claim 21 wherein the potential drug-binding substrates are phage display libraries.

### Claim 25 (depends on 20, 21)

The method of claim 20 or claim 21 wherein the drug-binding substrates are molecularly imprinted polymers.

### Claim 26 (depends on 20, 21)

The method of claim 20 or claim 21 further comprising the step of contacting the potential drug-binding substrates with a solution of a third drug substance exhibiting said known biological activity and identifying those substrates that exhibit specific binding affinity to at least two of said drug substances.

### Claim 27 (depends on 20, 21)

The method of claim 20 or claim 21 wherein the step of identifying those substrates that specifically bind to the drug substance comprises the step of analyzing the concentration of the drug substance in the test solution after contact with the substrate said analysis comprising mass spectrographic analysis of a volume of the test solution.

### Claim 28

A composition for analysis or screening of compounds for potential biological activity, said composition comprising at least first and second drug-binding substrates, said first substrate exhibiting a specific binding affinity to a first drug substance having a known biological activity deriving from its specific binding to one or more related endogenous molecules and said second drug-binding substrate exhibiting specific binding affinity to the same drug substance or to another drug substance having the same or similar biological activity as the first drug substance.

### Claim 29 (depends on 28)

The composition of claim 28 wherein the first and second drug-binding substrates exhibit specific binding affinities to another drug substance other than the first or second drug substance but having the same or similar biological activity as the first and second drug substances.

### Claim 30 (depends on 29)

The composition of claim 29 wherein the drug-binding substrates are monoclonal antibodies.

### Claim 31 (depends on 30)

The composition of claim 30 wherein the monoclonal antibodies are immobilized on solid support.

### Claim 32

A method for screening a set of exogenous test compounds for potential biological activity, said method comprising the steps of
selecting a monoclonal antibody exhibiting specific binding affinity for a control compound known to exhibit specific affinity for a biologically functional endogenous molecule in a living species;
contacting the set of test compounds with a drug-binding substrate comprising the antibody under conditions conducive to specific binding between the antibody and at least one of the test compounds to form an antibody-test compound complex;
separating at least a portion of the complex from at least a portion of the non-complexed test compounds;
identifying the complexed test compound; and
measuring the affinity of the test compound forming the antibody-test compound complex for the biologically functional endogenous molecule.

### Claim 33 (depends on 32)

The method of claim 32 wherein the control compound is a drug substance.

### Claim 34 (depends on 32, 33)

The method of claim 32 or claim 33 wherein the selected antibody exhibits specific affinity for at least one other control compound known to exhibit specific affinity for the biologically functional endogenous molecule.

### Claim 35 (depends on 32)

The method of claim 32 wherein the complexed test compound is identified by a procedure comprising mass spectroscopy.

### Claim 36 (depends on 32, 33)

The method of claim 32 or claim 33 wherein the antibody exhibiting specific affinity for the control compound also exhibits specific affinity for at least two other control compounds known to exhibit affinity for the biologically functional molecule.

### Claim 37 (depends on 32)

The method of claim 32 wherein the biologically functional molecule is an enzyme.

### Claim 38 (depends on 32)

The method of claim 32 wherein the biologically functional molecule is a transport protein.

### Claim 39 (depends on 32)

The method of claim 32 wherein the biologically functional molecule is selected from the group consisting of enzymes, receptors, ion channels, carrier molecules, and nucleic acids.

### Claim 40 (depends on 32, 33)

The method of claim 32 or claim 33 further comprising the step of contacting the set of test compounds with a second antibody exhibiting specific affinity for the first and second control compounds and identifying the test compounds that form antibody-test compound complexes with each antibody.

### Claim 41 (depends on 32, 33)

The method of claim 32 or claim 33 wherein the set of test compounds comprises member compounds of a combinatorial chemical library.

### Claim 42 (depends on 32, 33)

The method of claim 32 or claim 33 wherein the set of test compounds comprises a natural product comprising an extract of a plant, fungus, bacterial or marine species.

### Claim 43

A method for screening a set of test compounds for potential biological activity, said method comprising the steps of contacting a solution of the set of test compounds or a subset thereof with a substrate comprising an antibody, a phage display library or a molecularly imprinted polymer exhibiting specific binding affinity for a control compound known to exhibit specific affinity for a biologically functional molecule, said contacting step being carried out under conditions conducive to specific binding between the substrate and any test compounds to which it specifically binds to form one or more complexes of the substrate and the respective test compounds, separating the substrate-test compound complex from at least a portion of the solution, identifying a complexed test compound, and measuring the affinity of the complexed test compound for the biologically functional molecule.

### Claim 44 (depends on 43)

The method of claim 43 wherein the control compound is a drug substance.

### Claim 45 (depends on 43, 44)

The method of claim 43 or claim 44 wherein the substrate comprises a monoclonal antibody or a phage display library.

### Claim 46 (depends on 43, 44)

The method of claim 43 or claim 44 wherein the substrate comprises a molecularly imprinted polymer surface formed to exhibit specific binding affinity for the control compound.

### Claim 47 (depends on 43, 44)

The method of claim 43 or claim 44 further comprising the step of determining the affinity of the test compound forming a complex with the substrate for the biologically functional molecule.

### Claim 48 (depends on 43, 44)

The method of claim 43 or claim 44 wherein the set of test compounds comprises members of a combinatorial library.

### Claim 49 (depends on 43, 44)

The method of claim 43 or claim 44 wherein the set of test compounds comprises an extract of tissue of plant, fungal, microbial, or marine origin.

### Claim 50 (depends on 43, 44)

The method of claim 43 or claim 44 wherein the substrate exhibits specific affinity for at least one other control compound known to exhibit specific binding affinity for the biologically functional molecule.

### Claim 51 (depends on 43, 44)

The method of claim 43 or claim 44 wherein the solution of test compounds is contacted with at least first and second substrates, said first substrate exhibiting specific binding affinity for a first control compound known to exhibit specific binding affinity for the biologically functional molecule and said second substrate exhibiting specific binding affinity either for said first control compound or for a second control compound known to exhibit specific binding affinity for the biologically functional molecule.

### Claim 52

A complex useful for predicting biological activity of a test compound not known to exhibit said biological activity or to exhibit specific binding to an endogenous molecule associated with said biological activity, said complex comprising said test compound specifically bound to a substrate known to exhibit specific binding affinity for a drug substance known to exhibit said biological activity.

### Claim 53 (depends on 52)

The complex of claim 52 wherein the substrate is selected from the group consisting of an antibody, a member of a phage display library, and a molecularly imprinted polymer substrate.

### Claim 54 (depends on 52)

The complex of claim 52 wherein the substrate is a monoclonal antibody raised against the drug substance.

### Claim 55 (depends on 53)

The complex of claim 53 wherein the substrate exhibits specific binding affinity for at least one other drug substance known to exhibit said biological activity.

### Claim 56 (depends on 54)

The complex of claim 54 wherein the substrate exhibits specific binding affinity for at least one other drug substance known to exhibit said biological activity.

### Claim 57

An apparatus for screening test compounds for biological activity, said apparatus comprising a solid substrate exhibiting specific binding affinity for a control compound having known biological activity;
a vessel for containing a solution comprising a test compound and the control compound, optionally covalently linked to a detectable label, in contact with said substrate;
a detector for sensing the formation of substrate-test compound complexes; and
a chromatographic system for separating the control compound from at least a portion of the test compounds.

### Claim 58 (depends on 57)

The apparatus of claim 57 wherein the chromatographic system is HPLC.

### Claim 59 (depends on 57)

The apparatus of claim 57 wherein the solid substrate comprises an antibody, a member of a phage display library, or a molecularly imprinted polymer surface.

### Claim 60 (depends on 57)

The apparatus of claim 57 wherein the substrate exhibits specific binding affinity for at least one other control compound known to exhibit the biological activity.

### Claim 61 (depends on 57)

The apparatus of claim 57 wherein the control compound is a drug substance.

### Claim 62 (depends on 61)

The apparatus of claim 61 wherein the substrate comprises a monoclonal antibody.

### Claim 63 (depends on 57)

The apparatus of claim 57 wherein the detector comprises a mass spectrometer.

### Claim 64 (depends on 57)

The apparatus of claim 57 wherein the detector comprises a fluorescence detector.

### Claim 65

A kit for analysis or screening of test compounds for potential biological activity, said kit comprising at least first and second monoclonal antibodies, said first monoclonal antibody being raised against a first drug substance having a biological activity, and said second monoclonal antibody being raised against either said first drug substance or a second drug substance having said same biological activity, and wherein said monoclonal antibodies exhibit specific binding to a drug substance other than the drug substances against which each of said monoclonal antibodies was raised.

### Claim 66

A kit for analysis or screening of test compounds for potential biological activity, said kit comprising at least first and second monoclonal antibodies, said first monoclonal antibody being raised against a first drug substance having a predetermined biological activity and said second monoclonal antibody being raised against another drug substance having the same or a different biological activity.

### Claim 67 (depends on 66)

The kit of claim 66 wherein each of said first and second antibodies exhibit specific binding to another drug substance having the same biological activity as the drug substances against which the antibodies were raised.

### Claim 68

A method of using a monoclonal antibody for screening test compounds of unknown biological activity for a probable biological activity, said method comprising the steps of selecting a monoclonal antibody raised against a drug substance exhibiting said biological activity and capable of specific binding to said drug substance and at least one other drug substance known to exhibit said biological activity,
contacting said monoclonal antibody with a solution comprising said test compounds;
detecting the formation of an antibody-test compound complex formed by specific binding of the antibody to a test compound;
identifying the test compound forming the antibody-test compound complex; and
testing said test compound for said biological activity.

### Claim 69 (depends on 68)

The method of claim 68 further comprising the step of separating at least a portion of the antibody-test compound complex from at least a portion of the test compound solution.

### Claim 70 (depends on 68, 69)

The method of claim 68 or claim 69 wherein two or more monoclonal antibodies are immobilized on solid substrates.

### Claim 71 (depends on 68, 69)

The method of claim 68 or claim 69 wherein the solution further comprises the drug substance covalently linked to a detectable label.

### Claim 72 (depends on 68, 69)

The method of claim 68 or claim 69 wherein the solution further comprises the drug substance.

### Claim 73 (depends on 68, 69)

The method of claim 68 or claim 69 wherein the formation of the complex is detected by a method comprising mass spectroscopy.

### Claim 74 (depends on 68, 69)

The method of claim 68 or claim 69 wherein the formation of the complex is detected by a method comprising chromatography.

### Claim 75

A method for screening a set of exogenous test compounds of unknown biological activity for potential biological activity, said method comprising the steps of selecting a drug-binding substrate exhibiting specific affinity for a drug substance having said biological activity known to derive from specific binding to one or more related endogenous molecules;
contacting said substrate with a test solution comprising said set of test compounds or a subset thereof under conditions known to be conducive to binding of said drug-binding substrate to the drug substance;
separating the test solution from the drug-binding substrate and any test compounds specifically bound to said drug-binding substrate;
separating test compounds specifically bound to said substrate from said substrate and from each other to provide at least one substantially pure test compound;
identifying the test compounds that specifically bind to the drug-binding substrate; and
assaying those identified test compounds for the biological activity.

### Claim 76 (depends on 75)

The method of claim 75 wherein the drug-binding substrate is an antibody.

### Claim 77 (depends on 75)

The method of claim 75 wherein the drug-binding substrate exhibits specific binding affinity for at least first and second drug substances having the biological activity.

### Claim 78 (depends on 75)

The method of claim 75 wherein the drug-binding substrate comprises at least two unique drug-binding substrates which exhibit specific binding affinity for a drug substance having the biological activity.

### Claim 79 (depends on 75)

The method of claim 75 wherein the drug-binding substrate is a monoclonal antibody.

### Claim 80 (depends on 75)

The method of claim 75 wherein the drug-binding substrate comprises a phage display library.

### Claim 81 (depends on 75)

The method of claim 75 wherein the drug-binding substrate comprises a molecularly imprinted polymer

### Claim 82 (depends on 75)

The method of claim 75 wherein the contacting of the drug-binding substrate with the test solution, the washing of the drug-binding substrate and the separation of the test compounds that specifically bind to the drug-biding substrate from the drug-binding substrate is carried out by affinity chromatography.

### Claim 83 (depends on 75)

The method of claim 75 wherein the step of separating and identifying the test compounds that specifically bind to the drug-binding substrate comprises the step of chromatographically separating said compounds and subjecting same to physicochemical evaluation, structure elucidation or confirmatory testing for binding affinity to a drug-binding substrate.

### Claim 84 (depends on 75)

The method of claim 75 wherein the set of test compounds is a natural product comprising an extract of tissue, plant, fungal, microbial or marine origin.

### Claim 85 (depends on 84)

A substantially pure test compound having biological activity and prepared and identified in accordance with the method of claim 84.

### Claim 86 (depends on 75)

The method of claim 75 wherein the test compounds are members of a combinatorial chemical library.

### Claim 87 (depends on 75)

The method of claim 75 wherein a test compound identified to bind specifically to the drug-binding substrate is tested for its capacity for specific binding to the one or more related endogenous molecules.

### Claim 88 (depends on 87)

The method of claim 87 wherein each of said monoclonal antibodies forming the drug-binding substrate exhibit specific binding affinity to two or more drug substance having the biological activity.

### Claim 89 (depends on 88)

The method of claim 88 wherein the drug-binding substrate comprises a monoclonal antibody raised against a test compound previously identified to exhibit specific binding affinity to a monoclonal antibody exhibiting specific binding affinity to the drug substance.

### Claim 90

In a method for detection or analysis of specific binding affinity between an endogenous compound known to mediate a biological function, or a derivative or analog thereof, and one or more test compounds in a set of test compounds comprising potential drug substances to identify those test compounds having potential biological activity deriving from specific binding to said endogenous molecule, wherein such method the endogenous compounds or a derivative or analog. thereof is labeled with a detectable label and subjected to capillary electrophoresis in the presence of one or more test compounds, the improvement comprising the step of substituting at least one monoclonal antibody for said endogenous compound or derivative or analog thereof, said monoclonal antibody being selected from those monoclonal antibodies that specifically bind to at least one drug substance known to bind specifically to said endogenous molecule to affect its biological activity and produce a therapeutic effect

### Claim 91 (depends on 90)

The improved method of claim 90 wherein the monoclonal antibody is capable of specific binding to at least two drug substances known to specifically bind to said endogenous molecule.

### Claim 92 (depends on 91)

The improved method of claim 91 wherein the monoclonal antibody is fluorescently labeled.

### Claim 93

An anti-drug substance antibody having a detectable label and capable of binding specifically to the drug substance against which it was raised and to at least one other drug substance having the same or similar biological activity.

### Claim 94 (depends on 92)

The anti-drug substance antibody of claim 92 wherein the antibody is a monoclonal antibody.

### Claim 95 (depends on 93, 94)

The anti-drug substance antibody of claim 93 or claim 94 wherein the label is covalently linked to the antibody.

### Claim 96 (depends on 95)

The anti-drug substance antibody of claim 95 wherein the label is a fluorescent label.

### Claim 97

In a method for screening a set of test compounds to identify those test compounds having potential biological activity, said method comprising the step of measuring or detecting the specific binding of said test compounds to a biologically functional molecule known to be associated with said biological activity or a chemically related derivative or analog thereof, the improvement comprising the step of substituting a monoclonal antibody for said biologically functional molecule, said antibody being selected for its specific binding affinity to a drug substance known to exhibit said biological activity.

### Claim 98 (depends on 97)

The improved method of claim 97 wherein the antibody is selected for its specific binding affinity to at least two drug substances known to exhibit said biological activity.

### Claim 99 (depends on 97, 98)

The improved method of claim 97 or claim 98 wherein the method measuring or detecting comprises immobilizing the antibody on a sensor chip, contacting the chip with a solution of a test compound and measuring the change in surface optical characteristics of the sensor chip using surface plasmon resonance.

### Claim 100 (depends on 97, 98)

The improved method of claim 97 or claim 98 wherein the method of measuring or detecting comprises the step of subjecting the antibody and the test compounds to capillary zone electrophoresis.
